Early Clinical Experience With Risperidone Long-Acting Injection: A Prospective, 6-Month Follow-Up of 100 Patients
J Clin Psychiatry 2004;65(8):1076-1083
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: The use of risperidone long-acting injection (RLAI) is reasonably well supported by controlled studies. Little is known about treatment outcomes in patients receiving RLAI in clinical practice. Method: All prescribers in the South London and Maudsley Trust, London, United Kingdom, were informed that RLAI could be ordered for suitable patients with a DSM-IV diagnosis of schizophrenia or schizoaffective disorder: those known to be noncompliant with oral atypical antipsychotics and those intolerant of the adverse effects of conventional depot antipsychotics. Prescribers provided treatment and clinical progress data at the time of each prescription. Data collected included reason for prescribing RLAI, Clinical Global Impressions scale (CGI) score, inpatient or outpatient status, and details of all medications prescribed. All treatment discontinuations were investigated. The study was conducted from August 2002 to August 2003.
Results: Outcome could be determined for 100 subjects. Seventy-nine subjects (79%) were hospitalized when RLAI was initially prescribed. Mean duration of stay before RLAI initiation was 97 days (range, 0-1492 days). Most subjects were switched to RLAI from oral atypical (58%) or conventional depot (28%) antipsychotics. The main reason given for prescribing RLAI was poor patient acceptability of previous treatments (79%). Overall, 51% of the subjects discontinued RLAI. The main reason for discontinuation was lack of effect (24 subjects). No patient-related factor predicted outcome. CGI scores improved from a mean of 4.7 to 3.6 over the study period (p < .001). Overall, 61 subjects (61%) showed an improvement in CGI scores between baseline and endpoint. Antipsychotic coprescriptions were reduced from 71% of subjects to 8%. In completers, 23 (61%) of 38 subjects beginning RLAI as inpatients were discharged. The modal dose of RLAI was 25 mg every 2 weeks.
Conclusion: RLAI was moderately effective in clinical practice as judged by attrition from treatment. CGI score changes and discharge rates also suggest moderate effectiveness. RLAI was well tolerated. Antipsychotic coprescription was infrequent.